Related Experiment Video
Updated: Jan 6, 2026
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection
Martino Deidda1, Valentina Mercurio2, Alessandra Cuomo3
1Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato-Cagliari, Italy. martino.deidda@tiscali.it.
Abstract:
Despite advances in supportive and protective therapy for myocardial function, cardiovascular diseases due to antineoplastic therapy-primarily cardiomyopathy associated with contractile dysfunction-remain a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators are searching for alternative strategies that can timely recognise cardiovascular damage-thus permitting a quick therapeutic approach-or prevent the development of the disease. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as tyrosine kinase inhibitors. In recent years, metabolomics has proved to be a practical tool to highlight fundamental changes in the metabolic state in several pathological conditions. In this article, we present the state-of-the-art technology with regard to the metabolic mechanisms underlying cardiotoxicity and cardioprotection.
Insights
Cancer therapies can harm the heart, causing cardiomyopathy. Researchers are exploring metabolomics to detect and prevent this cardiotoxicity, improving cancer patient outcomes.
Area of Science:
- Cardiology
- Oncology
- Metabolomics
Background:
- Cardiovascular diseases, particularly chemotherapy-induced cardiomyopathy, are significant causes of morbidity and mortality in cancer patients.
- Current supportive therapies have limitations, necessitating novel strategies for early detection and prevention of cardiotoxicity.
- Both traditional chemotherapy (e.g., anthracyclines) and targeted therapies (e.g., tyrosine kinase inhibitors) can induce cardiac damage.
Purpose of the Study:
- To review the current understanding of metabolic mechanisms underlying cancer therapy-related cardiotoxicity.
- To highlight the role of metabolomics in identifying early signs of cardiac damage.
- To explore how metabolomics can inform cardioprotective strategies.
Main Methods:
- Review of existing literature on cardiotoxicity from antineoplastic therapies.
- Discussion of the application of metabolomics in studying metabolic alterations in cardiovascular conditions.
- Synthesis of current knowledge on metabolic pathways involved in cardiotoxicity and cardioprotection.
Main Results:
- Metabolomics offers a powerful approach to detect subtle metabolic changes indicative of cardiotoxicity.
- Understanding metabolic mechanisms can guide the development of targeted cardioprotective interventions.
- Early identification of metabolic shifts may enable timely therapeutic adjustments to mitigate cardiac damage.
Conclusions:
- Metabolomics is a promising tool for early detection and understanding of cancer therapy-induced cardiotoxicity.
- Further research into metabolic pathways is crucial for developing effective cardioprotection strategies.
- Integrating metabolomic insights into clinical practice could improve cardiovascular outcomes for cancer patients.
